Cwm LLC Buys 83,604 Shares of 10x Genomics $TXG

Key Points

• Cwm LLC increased its stake in 10x Genomics by 170.9% during Q2, acquiring an additional 83,604 shares, and now owns 132,510 shares valued at approximately $1.53 million.
• Several institutional investors, including ARK Investment Management and UBS Asset Management, also boosted their positions in 10x Genomics, indicating strong institutional interest in the stock.
• 10x Genomics reported a surprising profit of $0.28 per share for the last quarter, significantly exceeding analysts' expectations, and has a quarterly revenue of $172.91 million, marking a 12.9% year-over-year increase.

Cwm LLC grew its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 170.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 132,510 shares of the company's stock after acquiring an additional 83,604 shares during the quarter. Cwm LLC owned 0.11% of 10x Genomics worth $1,534,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in TXG. ARK Investment Management LLC lifted its position in shares of 10x Genomics by 7.5% during the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock valued at $112,143,000 after purchasing an additional 901,656 shares in the last quarter. Vanguard Group Inc. increased its stake in 10x Genomics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock valued at $97,061,000 after buying an additional 184,537 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of 10x Genomics by 235.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after buying an additional 4,987,195 shares in the last quarter. Millennium Management LLC boosted its stake in shares of 10x Genomics by 434.5% in the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after buying an additional 4,371,327 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of 10x Genomics by 134.4% in the 1st quarter. AQR Capital Management LLC now owns 1,212,429 shares of the company's stock worth $10,585,000 after buying an additional 695,227 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

Shares of 10x Genomics stock opened at $11.83 on Monday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -16.90 and a beta of 2.05. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $18.21. The stock's 50-day simple moving average is $12.87 and its 200 day simple moving average is $11.19.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

TXG has been the topic of a number of recent analyst reports. Zacks Research upgraded 10x Genomics from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 9th. UBS Group lifted their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Barclays reissued an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Piper Sandler started coverage on shares of 10x Genomics in a report on Thursday, September 11th. They set a "neutral" rating and a $15.00 price objective for the company. Finally, Morgan Stanley dropped their target price on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, 10x Genomics has an average rating of "Hold" and a consensus price target of $13.65.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares of the company's stock, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company's stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock worth $539,865. Corporate insiders own 10.03% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.